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Brett Glotzbecker,1 Christine Duncan,1,2 Edwin Alyea, III,1 Bonnie Campbell,1 Robert Soiffer1Morbidity is increased in patients undergoing hematopoietic stem cell transplantation when drug–drug inter-
actions lead to unexpected outcomes. These interactions occur as a result of exposure to complicated med-
ical regimens with drugs with narrow therapeutic windows and high toxicity profiles. In this report, we
review the available evidence and possible mechanisms of the most clinically relevant drug interactions, in-
cluding those involving inhibitors and inducers of the P450 isoenzyme system. We identify key interactions
that should be familiar to any physician caring for patients after hematopoietic stem cell transplantation. We
discuss drug metabolism in children and in the elderly and examine how age-related differences in metabo-
lism make complicate drug regimens in these populations. A better understanding of these interactions and
the responsible mechanisms will promote efficient delivery of the safest medical regimens to patients under-
going hematopoietic stem cell transplantation.
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Patients undergoing hematopoietic stem cell trans-
plantation (HSCT) are treated with complex medical
regimens combining chemotherapeutic, immunosup-
pressive, and antimicrobial agents, which in various
combinations carry the potential for multiple adverse
drug–drug interactions. The frequent multiple comor-
bidities in this patient population, including renal and
liver dysfunction, poor nutritional status, and altered
protein binding, amplify the risk of clinically significant
drug interactions. Literature detailing drug interac-
tions is often difficult to interpret, given the great dis-
parities in how reactions are defined and the widely
varying severity of responses among individuals. In ad-
dition, althoughmany interactions between pharmaco-
logic agents may be recognized in theory, all of these
interactions are not necessarily clinically significant.
In this article, we review the drug–drug interactions
with which transplantation physicians should be most
familiar to reduce adverse events secondary to poly-1Department of Medical Oncology, Dana-Farber Cancer
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6/j.bbmt.2011.11.029pharmacy.We focus primarily on the clinically relevant
pharmacokinetic drug interactions that occur in trans-
plantation regimens and offer recommendations for
preventing and/or managing those adverse events.BACKGROUND
Mechanisms of Drug–Drug Interactions
Drug interactionsmaybecategorized as eitherphar-
macodynamic or pharmacokinetic based on the mecha-
nism of interaction [1,2]. Pharmacodynamic drug
interactions result from the physiological activities of
two interacting drugs. Pharmacodynamic interactions
may be additive, synergistic, or antagonistic and may
result in increased or decreased therapeutic and/or
adverse effects of a specific drug. Pharmacokinetic
drug interactions lead to altered concentrations of
a drug or its metabolites resulting from changes in
absorption, distribution, metabolism, or elimination.
Interactions between two or more drugs may affect
any of the stages of drug metabolism. The most
common sites of interaction are in the intestinal lumen
and liver during CYP450-mediated metabolism.
Drug Metabolism
The liver is the site of metabolism for the majority
of drugs introduced into the body. It processesmedica-
tions viamechanisms known as phase I and phase II reac-
tions. During phase I reactions, a functional group is
introduced into the fat-soluble substrate, leading to989
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nation by the kidney. In phase II reactions, the parent
drug or the phase I product is conjugated to glucuronic
acid or glutathione, leading to a more water-soluble
product, which can then be excreted by the kidney or
in bile [2].
The isoenzymes of the CYP450 superfamily,
which are ubiquitously expressed in the liver and intes-
tinal lumen, are responsible for the majority of phase I
reactions. Thus, the most clinically relevant and dan-
gerous interactions involve metabolism mediated by
the CYP450 system. More than 50 genes have been
identified in humans, but only the following isoenzyme
pathways are known to be responsible for the majority
of identified metabolic drug interactions: CYP1A2,
CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1,
and CYP3A4. CYP3A4 is the isoform most frequently
associated with severe drug interactions, because it is
involved in the metabolism of 60% of all drugs in the
liver and 70% of all drugs in the intestine [1].
Mutations in a CYP450 enzyme may lead to
a change in normal enzymatic function. These genetic
polymorphisms have been described for CYP1A2,
CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP
3A4/5 enzymes. Some of the more common polymor-
phisms occur in CYP3A5, CYP2C9, and CYP2C19,
and each differs among populations and races. The fre-
quency of theCYP3A5*3 polymorphism is 60% to 70%
in Asians and up to 85% to 95% inCaucasians. Approx-
imately 40% of the Caucasian population are carriers of
alleles that encode for a partially defective CYP2C9 en-
zyme, and up to 25% of the Japanese population are
poor CYP2C19 metabolizers. Genetic variability can
amplify the production of toxic metabolites or inhibit
the metabolism of a prodrug, leading to detrimental ef-
fects [3]. Along with genetic variations in drug metabo-
lism are sex-related variations. Women showed a small
but significant increase in CYP3A activity, although
whether this translates to clinical differences in thera-
peutic drug effects is unclear [4].
CYP-mediated drug interactions can occur by two
separate mechanisms: enzyme inhibition and enzyme
induction. Inhibition can occur either by direct inacti-
vation or by mutual competition of substrates at a cat-
alytic site. Inhibition of metabolism via the CYP
pathway leads to increased peak or trough concentra-
tions and elimination half-lives, increasing the poten-
tial for toxic side effects. The onset of inhibition
occurs within 1 to 3 days.
The extent to which an inhibitor affects the metab-
olism of another drug depends on factors such as the
dosage and the inhibitor’s ability to bind to the enzyme.
In theory, drugs metabolized by the same CYP isoen-
zyme can compete at binding sites formetabolism, pos-
sibly leading to altered drug levels. Induction involves
increased synthesis or decreased breakdown of CYP
isoenzymes. Increased metabolic activity of the CYPsystem results in decreased plasma levels of the sub-
strate, decreased efficacy, and possibly therapeutic fail-
ure of the medication. Induction takes a longer time,
with maximal effect occurring over days to weeks [1,2].
Another potential mechanism of drug interaction
is at the site of membrane transporters. Because the
number of binding sites of drug transporters is limited,
drug–drug interactions at the binding sites may occur,
depending on the drugs’ pharmacokinetic properties.
A common transporter involved in drug interactions
is P-glycoprotein (P-gp), the product of the multidrug
resistance gene (MDR1) present in the kidneys, liver,
and endothelial cells of the blood-brain barrier. Ad-
ministration of a drug that inhibits or induces P-gp
can increase or decrease the renal elimination of
P-gp substrates and lead to increased or decreased
bioavailability in the intestine [1,2].
As a result of these interactions in the intestine and
liver, presystemic first-pass metabolism is a unique
concern for many drugs administered orally. When
taken orally, a drug is first absorbed in the gut and
then reaches the systemic circulation via the liver.
First-pass metabolism occurs in both the gastrointesti-
nal mucosa and the liver. The CYP450 enzyme system
in the intestinal mucosa can either inhibit or induce
drugmetabolism, and the P-gp transporter in the small
intestine can act as an efflux pump, presenting a barrier
to drug absorption [1]. Once the drug reaches the liver,
a significant portion is oxidized or reduced by hepatic
CYP450 metabolizers. To account for first-pass me-
tabolism, many of the drugs used by transplantation
physicians require dosage adjustment when changing
from the i.v. form to the oral form and vice versa.
Drugs that undergo extensive first-pass metabolism
in adults include calcineurin inhibitors and flucona-
zole, among others [2,5].THERAPY-SPECIFIC INTERACTIONS
Chemotherapy
Several chemotherapeutic agents, including busul-
fan and etoposide, used in conditioning regimens for
HSCT are dependent on the CYP450 enzyme system
formetabolism to inactivemetabolites and elimination.
Other agents, such as cyclophosphamide, depend on
conversion from a prodrug to an active metabolite to
become functional. Based on competition at these sites,
drug interactions occurring as early as the conditioning
phase of stem cell transplantation are of concern.
Alkylating Agents
Busulfan
Busulfan (1,4-bis [methanesulfonyl-y] butane) is
a bifunctional alkylating agent that has been used as
a conditioning regimen for more than 20 years.
Table 1. Busulfan Drug–Drug Interactions
Drug Mechanism Effect Recommendation Data Type
Acetaminophen Competition for glutathione Increased busulfan serum level Do not use 72 hours before or
72 hours after busulfan
administration.
Theoretical based on
metabolism of agents [13]
Itraconazole, voriconazolea Reduced busulfan clearance Increased busulfan serum level Use with caution; monitor
for adverse effects of busulfan;
consider fluconazole as an
alternative.
PK, HSCT [11]
Metronidazole Inhibition of CYP3A4;
competition for glutathione
Increased busulfan trough level Do not use 72 hours before or
72 hours after busulfan
administration.
PK, prospective HSCT [12]





of busulfan to guide levels.
CR, PK [7]
PK indicates pharmacokinetic studies; CR, case reports.
aVoriconazole interaction is theoretical based on the metabolism of the agent by the CYP450 3A4 system [14].
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a reaction with glutathione-S-transferase (GST) to
form a sulfonium ion of glutathione [6]. Although an-
imal studies have failed to show a role of the CYP450
system in the oxidative metabolism of busulfan, busul-
fan metabolism is known to be affected by CYP3A4
inducers, such as phenytoin [7]. Busulfan has a very
narrow therapeutic index, and several studies have
shown that toxicity depends on the area under the
receiver-operating characteristic curve (AUC) [8].
Close pharmacokinetic monitoring is critical when bu-
sulfan is administered orally. Oral busulfan is absorbed
erratically and is subject to hepatic first-pass metabo-
lism. This can result in low systemic concentrations
but high concentrations in the portal-hepatic venous
system, which conceivably may contribute to the
development of hepatic veno-occlusive disease [8]. As
a result, many centers have switched to i.v. dosing
to reduce pharmacokinetic variability and eliminate
cumbersome AUC monitoring [9,10].
Caution should be used when administering drugs
that compete with busulfan for clearance via the
glutathione pathway or interact with the CYP3A4
enzyme system (Table 1) [7,11-14]. The most
important interactions include those with phenytoin,
acetaminophen, and metronidazole.
Busulfan crosses the blood-brain barrier and can
lower the seizure threshold, most frequently with
high-dose regimens using every-6-hour dosing. In ran-
domized studies, once-daily dosing had similar phar-
macokinetic profiles and transplantation-related
complications as every-6-hour dosing [15]. For antisei-
zure prophylaxis, phenytoin historically has been used
with the high-dose therapy. In case reports of com-
bined busulfan and phenytoin, busulfan levels were
lower than predicted, most likely as a result of induc-
tion of both the GST and CYP3A4 systems [7]. An
alternative agent, such as levetiracetam, is recommen-
ded for antiseizure prophylaxis with high-dose bus-
ulfan [7,13]. Possibly through its interaction at theCYP3A4 isoenzyme, metronidazole also interferes
with busulfan metabolism, leading to an 80%
increase in busulfan trough level. Glutathione is
thought to act as a scavenger for the reactive
metabolites of metronidazole [16]. In a small prospec-
tive study of patients undergoing HSCT, patients who
received a combination of metronidazole and busulfan
showed elevated busulfan levels, elevated liver function
test values, and an increased prevalence of veno-
occlusive disease compared with those who received
busulfan alone [12]. Based on this small study, we do
not recommend using these two agents concurrently.
When metronidazole is used to treat a known infec-
tion, we recommend following similar guidelines as
for acetaminophen and starting metronidazole 72
hours after the completion of busulfan therapy [13].
Acetaminophen is another medication with a theo-
retical interaction with busulfan. Acetaminophen de-
creases glutathione levels in blood and tissues and
thus has the potential to inhibit the metabolism of bu-
sulfan. The manufacturer of Busulfex recommends not
administering acetaminophen within 72 hours before
starting or completing busulfan therapy, to avoid the
risk of myelosuppression, seizure, and veno-occlusive
disease [13].
A recent study examined the stability of the phar-
macokinetics of i.v. busulfan combined with fludara-
bine, a common reduced-intensity conditioning (RIC)
regimen for allogeneic HSCT. Two fludarabine-
containing RIC regimens were evaluated, and busulfan
clearance was determined to be independent of the
fludarabine dosage [10].
Carmustine
Carmustine (BCNU) is a mustard gas–related
a-chloro-nitrosourea compound used as an alkylating
agent in chemotherapy and as part of conditioning reg-
imens for autologousHSCT. BCNU ismetabolized to
both active and inactive species by CYP1A2-mediated
enzymes in the liver. The majority of the drug and its
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expired as carbon dioxide and 1% eliminated in feces
[17]. BCNU has very few documented pharmacoki-
netic drug interactions. A small study found that after
the administration of BCNU and cisplatin, patients on
oral phenytoin therapy showed decreased serum
phenytoin levels [18]. Based on this finding, the au-
thors recommended close monitoring of phenytoin
level when BCNU, and phenytoin are given concur-
rently, because increases in phenytoin dosage may be
necessary during treatment. Alternatively, patients
receiving these two drugs could be transitioned to
i.v. phenytoin [18] or given levetiracetam during
BCNU therapy.Cyclophosphamide
Cyclophosphamide, a cyclic phosphamide ester of
mechlorethamine, acts as an alkylating agent and is
extensively metabolized in the liver by the CYP450
system (CYP3A4, CYP2A6, CYP2B6, CYP2C8,
CYP2C9, and CYP2C19). The parent compound is
a prodrug that is not pharmacologically active until
converted to its active metabolites, phosphoramide
mustard and acrolein. Acrolein is thought to be re-
sponsible for cyclophosphamide-induced bladder tox-
icity. Between 5% and 25% of cyclophosphamide is
excreted unchanged in the urine [19]. In general, any
medication metabolized by one of the aforementioned
CYP450 enzymes has the potential for a pharmacoki-
netic interaction, and concurrent administration
should be done with caution.
In a retrospective study of 103 patients undergoing
HSCT, cyclophosphamide conditioning was associ-
ated with decreased cyclosporine serum concentra-
tions for up to 2 weeks after transplantation [20].
The authors hypothesized that this interaction was re-
lated to the autoinduction of cyclophosphamide,
which usually occurs within 24 hours of cyclophospha-
mide administration. Changes in cyclosporine levels
will occur fairly rapidly when the two drugs are used
concurrently. We recommend close monitoring of cy-
closporine level and appropriate dosage adjustments.
Because tacrolimus is also metabolized by the
CYP3A4 isoenzyme, concurrent administration with
cyclophosphamide carries similar concerns for an in-
teraction. Although there are no published studies
confirming this interaction, we believe that it is reason-
able to follow tacrolimus levels closely and adjust the
dosage appropriately.
The antiemetic aprepitant is also a CYP3A4 inhib-
itor. However, a recent randomized, double-blind pla-
cebo-controlled study of 40 patients undergoing
HSCT with either cyclophosphamide/busulfan or cy-
clophosphamide/total body irradiation conditioning
exposed to aprepitant or placebo 1 hour before the first
chemotherapy or radiation treatment showed no sig-nificant changes in cyclophosphamide pharmacokinet-
ics, and chemotherapy-induced nausea and vomiting
were well tolerated [21]. Based on that study, we feel
that aprepitant can be used safely with conditioning
regimens including cyclophosphamide.
Melphalan
Melphalan, synthesized from nitrogen mustard
and phenylalanine, is a bifunctional chloroethylating
alkylating agent that forms DNA cross-links and un-
dergoes rapid hydrolysis in the plasma to the inactive
metabolites monohydroxymelphalan and dihydroxy-
melphalan. Approximately 20% to 50% of melphalan
is eliminated in feces, and 10% is excreted by the kid-
neys [22]. Studies demonstrating clinically relevant
pharmacokinetic drug–drug interactions for stem cell
transplantation physicians are limited.
Thiotepa
Thiotepa is a polyfunctional alkylating agent of the
nitrogen mustard type. Cytoxicity results from the
formation of an unstable ethylenimmonium ion, which
alkylates intracellular molecular structures, including
nucleic acids, leading to disruption of DNA bonds.
Thiotepa is metabolized extensively in the liver by
CYP2B6 and CYP3A4 to its active metabolite triethy-
lene phosphoramide (tepa), and both thiotepa and tepa
are further conjugated to glutathione, which is cata-
lyzed by GST isoenzymes A1-1 and P1-1. Some
85% of thiotepa is excreted largely as metabolites
within 72 hours of administration [23]. Some case
reports suggest that drug interactions are related to
competition at the CYP3A4 and 2B6 enzymes.Other Agents
Carboplatin
Carboplatin is a cisplatin analogue with a mecha-
nism of action similar to that of alkylating agents.
Carboplatin is excreted renally, with 60% to 80%
eliminated in the first 24 hours after administration.
The platinum from degraded carboplatin binds irre-
versibly to plasma proteins and is eliminated slowly,
with an approximate half-life of 5 days [24]. Studies
in patients undergoing HSCT have suggested that
dosing based on AUC is more accurate and associated
with less hematologic toxicity compared with dosing
based on body surface area (BSA) [25]. In case reports,
patients receiving carboplatin and phenytoin had
decreased phenytoin levels, leading to recurrent sei-
zures; thus, frequent monitoring of phenytoin levels
both during and after treatment is recommended
[26]. Concomitant administration of carboplatin and
aminoglycosides was also associated with hearing loss
in several case reports; thus, an alternative antibiotic
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concerns about additive ototoxicity [27].
Etoposide
Etoposide (VP-16) is a semisynthetic podophyllo-
toxin derivative classified as a topoisomerase II ‘‘poi-
son,’’ the activity of which results in the stabilization
of cleavable complexes, causing irreversible DNA
damage and cell death in proliferating cells. VP-16 is
metabolized in the liver by the CYP450 enzymes,
including CYP3A4/3A5 and to O-demethylated me-
tabolites (catechol and quinine) via prostaglandin syn-
thases or myeloperoxidase. Up to 60% of VP-16 is
excreted renally unchanged from its original form.
Approximately 15% of the drug and its metabolites
are eliminated in feces, and 5% undergoes biliary ex-
cretion [28]. In general, any medication metabolized
by theCYP3A4 enzyme has the potential for a pharma-
cokinetic interaction, and caution should be used when
these medications are administered concurrently with
VP-16.
Fludarabine
Fludarabine phosphate is a fluorinated nucleotide
that is dephosphorylated in the plasma to free nucl-
eoside 9-b-D-arabinosyl-2-fluoroadenine (F-ara-A).
F-ara-A then enters cells and accumulates mainly as
the 5’-triphosphate F-ara-ATP. F-ara-ATP’s mode
of action is thought to be related to inhibition of
DNA and RNA synthesis by termination of chain
elongation after incorporation into DNA. Primary
elimination of fludarabine (40%-60%) occurs via the
kidneys [29]. This drug is generally well tolerated
with minimal drug interactions. As discussed earlier,
a recent study examining the pharmacokinetics of
busulfan when given in conjunction with fludarabine
as part of an RIC protocol found no significant inter-
action between the two agents [10].Immunosuppressive Agents
The calcineurin inhibitors and sirolimus, agents
commonly used in the prevention and treatment of
graft-versus-host disease after HSCT, have many
clinically significant drug–drug interactions related
to their metabolism by the CYP3A4/5 isoenzyme sys-
tem. Clinically significant interactions with the azole
antifungals [30-35], metronidazole [36], and PPIs
[37-39] have been reported. Concurrent use of these
agents with calcineurin inhibitors and sirolimus can
lead to elevated immunosuppressant concentrations,
with an associated risk of toxicity. Thus, levels of
cyclosporine, tacrolimus, and sirolimus should be
followed closely and adjusted appropriately. In
addition, after oral administration of a calcineurin
inhibitor, CYP450 enzymes in the intestine and liver
metabolize the drug, leaving only 25% to 50% of thedose bioavailable [1]. Based on this, we recommend
reducing the dose by one-half to one-third when
converting from oral to i.v. cyclosporine.
Tacrolimus
Tacrolimus is a calcineurin inhibitor that binds to
an immunophilin (FK-binding protein) in the cytosol,
which in turn, binds to the calcium/calmodulin-
dependent phosphatase calcineurin, resulting in inhi-
bition of IL-2 gene transcription and downstream
T cell activation. Tacrolimus has 100 times more
immunosuppressive activity in vitro than cyclosporine;
this allows the use of therapeutic trough concentra-
tions of tacrolimus, which are 20 times lower than
those for cyclosporine. Tacrolimus is metabolized
primarily by the CYP4503A4 system in the liver and
intestinal wall, with a minor contribution of P-gp.
Some 93% of the drug and its metabolites are elimi-
nated in bile, with\2% excreted as unchanged drug
in the urine [40].
Of note, the extimated percutaneous bioavaila-
bility of topical tacrolimus is 0.5% to 5% in adults.
Increased systemic absorption has been noted in pa-
tients with epidermal barrier defects. In patients
receiving topical tacrolimus as adjunctive therapy for
grade IV skin graft-versus-host disease with desqua-
mation, tacrolimus levels should be followed closely
[41,42].
The most clinically significant adverse drug
reactions are secondary to interactions at the CYP3A
enzyme or P-gp transporter. Table 2 lists the pharma-
cokinetically significant drug interactions with tacr-
olimus [37,38,42-53]. The most notable of these
interacting drugs are the antifungal azoles, which act
as both CYP3A4 and P-gp inhibitors and lead to
elevated serum tacrolimus levels. Interactions
between the azoles and the calcineurin inhibitors and
approaches to modifying the dosing of these drugs
are discussed in more detail in the section on
antifungal drugs. Other CYP3A4 inhibitors include
metronidazole and the proton pump inhibitors
(PPIs), including omeprazole. Of note, PPIs also
inhibit CYP2C19. Case reports and prospective
studies of Japanese liver and renal transplantation
recipients with CYP2C19 polymorphisms who
received PPI therapy have shown elevated tacrolimus
levels [37,38]. The use of rabeprazole, which has been
shown to have a minimal effect on tacrolimus levels,
has resulted in normalization of tacrolimus levels in
case-control studies [38]. Based on the foregoing stud-
ies, we recommendusing PPIs and tacrolimus concur-
rently only when necessary. The PPI of first choice
should be rabeprazole, if available [38]. If rabeprazole
is not on the formulary and a PPI is deemed preferable
to anH2 blocker, then low-dose omeprazole is a possi-
ble alternative. Varying results have been noted in case
reports and case-control studies evaluating the
Table 2. Tacrolimus (T) and Cyclosporine (C) Pharmacokinetic Drug–Drug Interactions
Drug Mechanism Data Type Effect Recommendation
CYP inhibitors
Amiodarone CYP3A4 inhibition CR; no clinical effect Increased T/C levels at
3 days to 4 weeks
If used concurrently, monitor T/C levels and adjust dosage; need
to monitor levels $4 weeks after adding amiodarone [53].
Azoles CYP3A4 and P-gp inhibition PK, CR, HSCT; renal Increased T/C levels Adjust dosage according to Table 5.
Estrogens CYP3A4 inhibition CR; no clinical effect Increased T/C levels If used concurrently, monitor T/C levels and adjust dosage [57].
Macrolides (not azithromycin) CYP3A4 inhibition CR; acute renal failure Increased T/C levels Avoid concurrent use; if used concurrently, monitor T/C levels [59].
Metronidazole CYP3A4 inhibition CR; no clinical effect Increased T/C levels If used concurrently, monitor T/C levels and adjust dosage [36].
Non-dihydropyridine CCBs CYP3A4 inhibition PK, CR; neurotoxicity Increased T/C levels Consider a 20% T/C dosage reduction on starting CCB; monitor
T/C levels [56].
Proton pump inhibitors CYP3A4/5 and CYP2C19 inhibition PK, renal/liver; CR, no clinical
effect
Increased Texposure If used concurrently, monitor T level and adjust dosage [38].
Imatinib/TKIs CYP3A4 inhibition
(nilotinib–P-gp inhibition)
Animal studies Increased T/C levels Monitor T/C levels [43].
Aprepitant CYP3A4 inhibition HSCT; no clinical effect Increased T/C levels Monitor T/C levels [45].
Statins CYP3A4 inhibition; OAT1B1 metabolism Randomized, renal, healthy, CR;
rhabdomyolysis with C
Increased statin AUC three- to 20-fold
(depending on statin used);
less interaction with T [47]
If used concurrently, consider lower initial and maintenance dose
of statins; monitor for rhabdomyolysis especially with C use
(stop statin immediately if it occurs) [53].
CYP inducers
Phenytoin CYP3A4 induction CR; no clinical effect Decreased T/C levels If used concurrently, monitor T/C level and adjust dosage [58].
Competition at CYP3A
Corticosteroids CYP3A4/P-gp induction CR/PK studies Decreased T/C levels If used concurrently, monitor T/C level during and after steroid
use [46].
CYP3A4 substrate CR; possibly increased
neurotoxicity
Increased T/C steroid levels If used concurrently, monitor T/C level; monitor for steroid
toxicity [61].
Dihydropyridine CCBs CYP3A4 substrate; P-gp inhibitor PK, CR; no clinical effect Increased T/C levels (nifedipine only T) If used concurrently, monitor T/C level [66].
Tacrolimus and cyclosporine Competition at CYP3A4 Based on metabolism and
additive toxicity
Decreased C metabolism [48] Discontinue T/C 24 hours before initiation of the other [42].
Sirolimus CYP3A4 competition PK; renal, volunteers Decreased T/C levels; increased
sirolimus AUC with C
If used concurrently, monitor T level and adjust dosage; sirolimus
should be administered 4 hours after oral C [51,60].
Nafcillin CYP3A4 competition CR; acute renal failure Decreased C level Avoid concurrent use (possible interference with assay) [63].
Other interactions
MMF Inhibition of enterohepatic recirculation PK; liver/renal Decreased MMF level Use caution if administering together; MMF dosage may need
adjustment [49,62].
Caspofungin Unknown PK; healthy, transplantation,
increased liver function test
values w/C
Increased T level; Increased AUC of
caspofungin with C
T is favored over C for coadministration with caspofungin; routine
monitoring of T level is suggested [52,64].
Octreotide Decreased C absorption CR; no clinical effect Decreased C effectiveness If used together, monitor C level; a C dosage increase of 50% at the
start of octreotide is suggested [67].
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have suggested that concurrent use has no effect on ta-
crolimus levels, whereas others have noted a continued
rise in levels despite a continuous or decreased dose of
PPI [54]. We recommend using omeprazole 20 mg
daily and following tacrolimus levels closely. If tacroli-
mus levels remain stable, continuing both agents to
minimize changes in the saturation of the isoenzyme
system would be beneficial. Other commonly used
CYP3A4 inhibitors include estrogens and tyrosine ki-
nase inhibitors (imatinib, nilotinib, and dasatinib).
For all of these drugs, tacrolimus levels should bemon-
itored and the dosages adjusted tomaintain therapeutic
levels.
The use of drugs that act as inducers of CYP3A4
can lead to decreased serum levels of tacrolimus and
thus merits close monitoring. The main inhibitor of
CYP3A4 is phenytoin. Although phenytoin may be
used concurrently with close monitoring of tacrolimus
levels, alternative antiseizure prophylaxis with levetir-
acetam could be considered as well [42]. Sirolimus also
competes for metabolism with tacrolimus at the
CYP3A4 isoenzyme, leading to diminished tacrolimus
levels [51]. Of note, a single-dose crossover study in
healthy subjects presented in the Astellas Prograf
product information insert suggested that concurrent
administration of tacrolimus and magnesium hydrox-
ide/aluminum hydroxide led to a 21% increase in the
mean tacrolimus AUC compared with administration
of tacrolimus alone [42].
Cyclosporine
Cyclosporine binds to a cytosolic protein, cyclo-
philin, in immunocompetent T cells. The resulting
complex inhibits calcineurin, which in turn decreases
IL-2 production. Cyclosporine also inhibits lympho-
kine production and IL release, resulting in reduced
effector T cell function. It has also been shown to
bind to calmodulin with low affinity, which is thought
to be associated with some of its toxicities. Like tacro-
limus, cyclosporine is metabolized primarily by the
CYP3A4 enzyme system in the liver and intestine. Im-
portantly, it also undergoes metabolism by the 3A5
system and acts as a substrate of P-gp in the intestine.
A previous study found that the quantity of intestinal
P-gp accounted for up to 17% of the variability in
oral cyclosporine pharmacokinetics. Approximately
90% of cyclosporine is bound to lipoproteins. Thema-
jority of cyclosporine is excreted in feces, with 6%
excreted by the kidneys [55].
Cyclosporine drug–drug interactions of potential
clinical relevance involve CYP450 enzyme metabo-
lism, as outlined in Table 2 [36,39,48,53,56-67].
Interactions resulting from the induction of CYP3A4
have been documented with the antifungal azoles
[30,32,68], metronidazole [36], PPIs [39], and estro-
gens [57]. Corticosteroids are CYP3A4 substrates.There are case reports of inhibition of CYP3A4 by cor-
ticosteroids, including methylprednisolone and pred-
nisone, leading to increased levels of both agents
[65]. A clear clinical effect from these increased expo-
sures has not been shown to date; thus, it is reasonable
to monitor cyclosporine levels and to assess for signs of
steroid excess when cyclosporine and corticosteroids
are used concurrently. Cyp3A4 inhibition by sirolimus
leads to increased sirolimus concentrations. A ran-
domized crossover trial of 24 stable kidney transplan-
tation recipients that evaluated the optimal timing of
cyclosporine and sirolimus administration found that
sirolimus AUC and trough levels were consistently
and significantly higher when the two drugs were ad-
ministered concomitantly than when they were admin-
istered 4 hours apart [60]. Based on these findings, the
authors recommended administering sirolimus 4
hours after oral cyclosporine dosing [60]. In vitro stud-
ies and some pharmacokinetic studies have suggested
that tacrolimus, like sirolimus, competes with cyclo-
sporine for metabolism by the P450 system [48].
When changing from one agent to the other, tacroli-
mus or sirolimus should be discontinued for 24 hours
before the other drug is initiated [42].
CYP3A4 inducers include phenytoin and possibly
nafcillin. Several case reports and retrospective studies
found that coadministration of phenytoin and cyclo-
sporine resulted in reduced cyclosporine levels [58].
Although nafcillin most likely induces CYP450 isoen-
zyme function, leading to decreased cyclosporine
levels, whether the interaction occurs only in vitro
and is clinically significant is unclear; thus, changes
to cyclosporine dosing should be made cautiously [63].
Some studies have also suggested that increased se-
rum creatinine and cyclosporine levels can result from
the concurrent use of cyclosporine and fluoroquino-
lones. However, a review of controlled studies and
case reports suggests that other factors contribute to
these adverse interactions. In pharmacokinetic studies,
cyclosporine levels were found to remain stable; it was
hypothesized that cyclosporine and ciprofloxacin are
metabolized by different CYP450 enzymes, making
an interaction even more unlikely [69]. Based on the
lack of consistent findings and definite, clinically sig-
nificant interactions, we believe that ciprofloxacin
may be safely coadministered with cyclosporine at rec-
ommended doses and with close monitoring of cyclo-
sporine levels.
Sirolimus
Sirolimus, a macrocyclic triene antibiotic pro-
duced by Streptomyces hygroscopicus, acts as an immuno-
suppressive and an antineoplastic agent. Although
structurally similar to calcineurin inhibitors, sirolimus
has a unique mechanism of action. It binds to FK-
binding protein 12 and forms a complex with themam-
malian target of rapamycin. The inactivation of the
Table 3. Sirolimus Drug–Drug Interactions
Drug Mechanism Data Type Effect Recommendation
Inhibitors
Amiodarone CYP3A4 inhibition CR; no clinical effect Increased sirolimus level If used concurrently, monitor sirolimus level
and adjust dosage [76].
Azoles CYP3A4 and P-gp
inhibition
PK, CR, HSCT; volunteers Increased sirolimus level Adjust according to Table 5.
Corticosteroids CYP3A4 inhibition PK Increased levels of both drugs If used concurrently, monitor sirolimus level;
monitor for signs of steroid side effects [71].
Cyclosporine CYP3A4 inhibition PK; renal, volunteers Increased sirolimus AUC Sirolimus should be administered 4 hours after
oral cyclosporine [60].
Macrolide antibiotics CYP3A4 inhibition
(potent)
CR; acute renal failure Increased sirolimus level Coadministration is not recommended [72,75].
Micafungin Unknown PK; volunteers Increased sirolimus level If used concurrently, monitor sirolimus levels
and adjust dose [122].
Non-dihydropyridine
diltiazem/verapamil
CYP3A4 inhibition PK; volunteers Increased sirolimus level If used concurrently, monitor sirolimus level
and adjust dosage [73].
Inducers
Phenytoin CYP3A4 induction CR; no clinical effect Decreased sirolimus level If used concurrently, monitor sirolimus level







Decreased tacrolimus level If used concurrently, monitor tacrolimus level
and adjust dosage [51].
PK indicates pharmacokinetic studies; CR, case reports.
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reduced DNA transcription, translation, protein syn-
thesis, and cell cycle arrest in the G1 phase in activated
lymphocytes. It also blocks the T cell response to
cytokines and inhibits B cell proliferation and immu-
noglobulin production. Sirolimus is metabolized ex-
tensively by the CYP3A system in the liver. Its
metabolites are excreted primarily in feces, with
\10% eliminated by the kidneys [70]. Table 3 lists
the clinically relevant interactions [42,51,60,71-76].
Of note, the interaction potential for sirolimus is
nearly identical to that of tacrolimus; a notable
difference is that sirolimus has a longer half-life, and
thus the changes in drug levels resulting from drug in-
teractions are delayed with sirolimus. Inhibitors of
CYP3A4 leading to increased concentrations of siroli-
mus include azoles [31,34,77], corticosteroids [71], and
cyclosporine [60]. Phenytoin acts as an inducer of the
isoenzyme, lowering the serum concentration of siro-
limus [74]. Tacrolimus also competes with sirolimus
for metabolism at CYP3A4, and studies in kidney
transplantation recipients have suggested decreased ta-
crolimus AUC values and serum levels when tacroli-
mus and sirolimus are administered concurrently [51].
Other Agents
Corticosteroids
Corticosteroids decrease inflammation by (1) stabi-
lizing the lysosomes in neutrophils, which prevents
degranulation and the resulting inflammatory re-
sponse; (2) inhibiting the enzyme phospholipase A2,
which in turn blocks synthesis of prostaglandins; and
(3) binding to glucocorticoid receptors, leading to
upregulation of anti-inflammatory genes. Corticoste-roids act as both substrates and inducers of the
CYP3A4/3A5 and P-gp pathways, affecting a patient’s
ability to tolerate numerous medications [78,79].
Corticosteroids also induce the uridine diphosphate–
glucuronosyl transferase enzymes and multidrug
resistance–associated protein 2, which are involved in
themetabolism ofmycophenolatemofetil (MMF) [80].
Table 4 lists the drug interactions resulting from
metabolic competition at the CYP isoenzyme or
P-gp pathways [46,53,65,71,81-87]. Depending on
the steroid used, the coingestion of azoles [83] and
estrogens [81] will contribute to side effects from
exposure to low or high levels of steroids. When
cyclosporine, tacrolimus, or sirolimus is administered
concomitantly with steroids, serum levels should be
followed and dosages adjusted as necessary to address
signs of steroid toxicity [42,61,71].
A clinically significant drug interaction unrelated
to the CYP or transporter systems is that with fluoro-
quinolones. Postmarketing surveillance reports sug-
gest that the risk of tendinitis or tendinosis is
increased in elderly patients on fluoroquinolone ther-
apy who are also receiving steroids [88]. Liposomal
amphotericin B also has a theoretical pharmacody-
namic interaction with steroids. The concomitant
use of amphotericin B and steroids carries a risk of po-
tentiating hypokalemia, warranting close monitoring
of serum electrolyte levels [89].
Methotrexate
Methotrexate is an antimetabolite that reversibly
inhibits dihydrofolate reductase, which interferes
with the purine nucleotide synthesis required for
DNA production and repair. Methotrexate is metabo-
lized hepatically and intracellularly to polyglutamate
Table 4. Corticosteroid Drug–Drug Interactions
Drug Mechanism Data Type Effect Recommendation
Inhibitors
Aprepitant CYP3A4 inhibition PK, healthy volunteers Increased methylprednisolone
and dexamethasone
If coadministered with aprepitant (125 mg
and 80 mg), decrease methylprednisolone
i.v. dosage by 25%/oral dosage by 50% and
dexamethasone dosage by 50% [85,87].






Decrease steroid dosage if steroid-related
adverse effects are seen [83,84].
Clarithromycin CYP3A4 inhibition PK, nonrandomized
asthma patients






Increased levels of both drugs Monitor CSA level and adjust; monitor for
corticosteroid-induced side effects/
seizures [61].
Estrogens CYP3A4 inhibition CR, PK, nonrandomized
healthy volunteers; no
clinical effects
Increased risk of prednisone
side effects
Monitor for steroid-induced side effects;









Monitor for corticosteroid-induced side
effects; may need to decrease steroid
dosage if on chronic concomitant
therapy [53].
Sirolimus CYP3A4 inhibition Based on metabolism Increased levels of both drugs Monitor sirolimus level and adjust dosage
[42,75].
Tacrolimus CYP3A4 inhibition Based on metabolism Increased tacrolimus level Monitor tacrolimus level and adjust
dosage [46].
Inducers




Monitor for steroid efficacy; dosage increase
may be necessary if the drugs are used
concomitantly [86].
PK indicates pharmacokinetic studies; CR, case reports.
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role in the metabolism of methotrexate. The majority
of i.v. methotrexate (80%-90%) is excreted unchanged
by the kidneys within 24 hours, with#10% cleared by
the biliary tract [90]. Although low-dose methotrexate
therapy is used for prevention of graft-versus-host dis-
ease, the concomitant use of medications with similar
antifolate mechanisms, such as trimethoprim/sulfame-
thoxazole, should be avoided [91].
MMF
MMF is a selective, noncompetitive, and reversible
inhibitor of inosine monophosphate dehydrogenase.
Its immunosuppressive effects are not present until it
undergoes first-pass metabolism by esterases in the
liver tomycophenolic acid.Mycophenolic acid inhibits
de novo guanosine synthesis, which is critical for
proliferation of T and B lymphocytes. An additional
mechanism that causes relevant drug interactions is
the metabolism of MMF by the multidrug resistance
protein 2 transporter and by uridine diphosphate-
glucuronosyltransferases. Approximately 93% of
MMF is excreted renally [92].
The most relevant drug interaction with MMF
occurs with cyclosporine. Cyclosporine inhibits the
multidrug resistance protein 2 transporter transporter,
which decreases the enterohepatic recirculation of
mycophenolic acid and in turn the plasma level of
MMF. Caution should be exercised when administer-
ing the two drugs concurrently, and the MMF dosagemay need to be adjusted when cyclosporine is added or
stopped [62].Antifungal Agents
Azoles
Azoles are widely used in stem cell transplantation
as antifungal prophylaxis and to treat presumed or di-
agnosed infections during periods of prolonged neu-
tropenia. Perhaps the most important interactions
are those between the azoles and cyclosporine and ta-
crolimus. These interactions are based on inhibition of
the CYP450 isoenzyme system and P-gp efflux pumps.
Of note, both competitive and noncompetitive inhibi-
tion occurs, and thus the changes in the AUCs of these
drugs often are not dose-dependent. Although the tim-
ing of the increased levels varies, most occur within 48
to 96 hours after starting the antifungal agent [93].
Table 5 presents the changes in AUC values of the
most commonly used immune suppressant agents after
initiation of the different azoles, along with suggested
dosage adjustments [30-35,68,77,94].
An important interaction that should be empha-
sized is that between voriconazole and sirolimus.Coad-
ministration of these two drugs is contraindicated,
given reports that this can lead to significantly in-
creased systemic exposure to sirolimus. Based on the
study of Marty et al. [34], when the two drugs are
used simultaneously, the sirolimus dosage should be re-
duced by 90%. Of note, azole antifungals also increase










Fluconazole oral 400 mg daily
[30,31,33]




Fluconazole i.v. 400 mg daily [5,35] 16% increase [35] 40% 21% increase [35] 25% - 25%
Voriconazole oral or i.v. 200 mg
twice daily [32,34,94]
300% increase 66% 70% increase 50% 1,000% increase 90%
Posaconazole oral 200 three
times/day [68,77]
350% increase 75% 33% increase 25% 8.9-fold increase 50%
aMonitoring of blood levels of calcineurin inhibitors is recommended when the route of fluconazole administration is switched from i.v. to oral [5]. AUC
indicates area under the curve.
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thus, when changing from i.v. to oral dosing of these
medications, a dosage reduction of the immunosup-
pressantmay be advisable, especially if the current level
is near the upper limit of the desirable range [5].
The azoles have clinically significant interactions
with many other drugs besides tacrolimus, cyclospor-
ine, and sirolimus, as summarized in Table 6. We dis-
cuss these interactions in more detail in the sections on
the individual azole drugs that follow. Azoles also have
been linked with increased levels of the antidiabetic
agents glipizide and glimepiride with concurrent ad-
ministration; a recent study has suggested that this oc-
curs through a CYP2C9-mediated mechanism and
involves primarily fluconazole and voriconazole [95].Table 6. Other Azole Drug Interactions
Drug Antifungal Data Type
Busulfan Flz Nonrandomized SCT Busulfan
Itz Nonrandomized SCT Busulfan





Itz Randomized healthy volunteers Felodipi
Flz, Vrz, Psz In vitro Felodipi
Dexamethasone Itz Randomized healthy volunteers Dexame
Estrogens Vrz Nonrandomized healthy volunteers Vrz and
Flz Randomized healthy volunteers Estroge
Fentanyl/oxycodone Flz, Vrz Randomized healthy volunteers Fentany
Glipizide/glimepiride Flz Randomized healthy volunteers Glimepi
Methadone Vrz Randomized patients taking
methadone
Methad
Flz Randomized patients taking
methadone
Methad
Phenytoin Psz Nonrandomized volunteers Psz AUC
Vrz Randomized volunteers Vrz AU
AUC
Flz Randomized volunteers Phenyto




Statins Itz/Psz Randomized volunteers Statin A
Flz Randomized volunteers Statin A
Vrz In vitro Statin A
TKIs Vrz/Psz In vitro TKI me
Flz indicates fluconazole; Itz, itraconazole; Psz, posaconazole; Vrz, voriconazoAlthough severe hypoglycemia has not been reported,
close monitoring of glucose levels when azoles and sul-
fonylureas are used concurrently seems a reasonable
recommendation.
Another clinical concern with the administration of
any azole is an increased risk of a prolonged QTc inter-
val.The concurrentuseof anazole andanother agent as-
sociated with prolonged QTc interval should be done
with caution, with close electrocardiography monitor-
ing during the course of therapy [96]. Commonly used
drugs that prolong the QTc interval include fluoroqui-
nolones (levofloxacin/moxifloxacin.ciprofloxacin), an-
tiemetics (eg, prochlorperazine), methadone, foscarnet,
pentamidine, and tyrosine kinase inhibitors, including
dasatinib and nilotinib [96].Effect Recommendation
AUC increased No action needed [11].
clearance decreased Avoid combination [11].
clearance decreased Consider starting Vrz after day 1 [11,13].
ne AUC increased Decrease felodipine dosage [108].
ne AUC increased Monitor blood pressure.
thasone AUC increased Monitor for toxicity [83].
estrogen AUC increased Monitor for Vrz toxicity [111].
n AUC increased No action needed [104].
l AUC increased Monitor for sedation [100].
ride AUC increased Decrease glimepiride dose [103].
one AUC increased Monitor for methadone toxicity, QT-interval
prolongation [110].
one AUC increased Monitor for methadone toxicity, QT-interval
prolongation [98].
decreased Avoid combination [114].
C decreased; phenytoin
increased
Increase Vrz maintenance dose to 400 mg
twice daily [109].
in AUC increased Monitor for phenytoin toxicity [99].
omeprazole AUC increased Do not use Itz capsules; solution okay [107].
C increased No clinically relevant effect; start with
low-dose PPI [102].
UC increased Avoid combination [115].
UC increased Start low-dose statin [101].
UC increased Monitor for statin toxicity [112].
tabolism decreased Avoid use with dasatinib/nilotinib, which
also increases the risk of QT-interval
prolongation; decrease dose if necessary.
If using with imatinib, consider using lowest
dose and closely follow for toxicity [43].
le; PK, pharmacokinetic studies; CR, case reports.
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Fluconazole is a triazole antifungal agent that in-
hibits fungal sterol synthesis. It is considered a fungi-
static agent. Approximately 10% to 20% of
fluconazole is metabolized by the CYP3A4 isoenzyme;
almost 80% of the agent is excreted unchanged by the
kidneys, with the rest excreted as metabolites. Al-
though only a small proportion of fluconazole is me-
tabolized by the CYP system, the drug remains
a moderate inhibitor of the CYP3A isoenzyme and
has the potential to interact with other drugs that are
metabolized at this site. Some clinical studies also
have suggested that fluconazole is a weak inhibitor of
the CYP2C9 enzyme [2,97].
Corticosteroids, estrogens, PPIs, and narcotics, in-
cluding oxycodone, fentanyl, and methadone, can also
interact with fluconazole, as summarized in Table 6
[11,98-104]. In one pharmacokinetic study, the
coadministration of fluconazole and methadone
resulted in a 35% average increase in the AUC of
methadone; thus, patients receiving both drugs
should be followed closely for signs of oversedation
[98]. The coadministration of phenytoin and flucona-
zole has led to elevated phenytoin levels in case reports
and small prospective studies [99]; thus, coadministra-
tion calls for a reduced phenytoin dosage and close
monitoring of serum levels.
Itraconazole
Itraconazole is a synthetic triazole antifungal agent
that blocks the C-demethylation step of CYP450-
dependent synthesis of ergosterol in the fungal wall
membrane. It is more potent than fluconazole but has
poor intestinal absorption in high gastric pH. It un-
dergoes hepatic metabolism by the CYP4503A system.
Nearly half is eliminated as metabolites in the kidneys,
with 3% to 18% excreted unchanged in feces [105].
Although itraconazole is used infrequently, it has
several unique interactions despite its similar metabo-
lism to fluconazole. The concurrent use of busulfan
and itraconazole results in reduced busulfan clearance
and increased risk of busulfan-related adverse effects,
including myelosuppression and pulmonary toxicity
[11]. Reduced itraconazole plasma concentrations
have been reported with concurrent use of alumi-
num-, calcium-, or magnesium-containing products.
Current recommendations caution against the concur-
rent use of antacids and itraconazole; however, if ant-
acids must be used, they should be administered at
least 1 hour before or 2 hours after itraconazole cap-
sules [106]. Significant drug interactions associated
with itraconazole are listed in Table 6 [11,107,108].
Voriconazole
Voriconazole is also a triazole antifungal that in-
hibits fungal CYP450-dependent ergosterol synthesisin the fungal wall membrane. It is metabolized by mul-
tiple CYP450 isoenzymes in the liver, including
CYP2C19, CYP2C9, and CYP3A4. It acts as both
a substrate and inhibitor of these enzymes. Less than
2% of voriconazole is excreted unchanged [14].
Given voriconazole’s extensive metabolism by the
CYP450 system, many clinically significant drug inter-
actions may occur. Dosage adjustments are recom-
mended when using voriconazole concurrently with
CYP450 metabolizers. For omeprazole, the maximum
recommended dose is 40 mg/day; alternative drugs in-
clude lansoprazole/pantoprazole and H2 blockers. In
patients concurrently receiving phenytoin, serum
levels of phenytoin and voriconazole should be closely
monitored; based on recent pharmacokinetic studies,
the phenytoin dose may need to be decreased by
60%, or the voriconazole dose increased from 200
mg to 400 mg twice a day or 3 to 4 mg/kg every 12
hours [109]. To avoid interactions with phenytoin,
an alternative antiseizure drug, such as levetiracetam,
might be considered. The significant drug interactions
associated with voriconazole are summarized in Table
6 [11,100,109-112].
Posaconazole
Oneof the newer triazole antifungals, posaconazole
blocks the synthesis of ergosterol in the fungal wall
membrane. Posaconazole is lipophilic, with .98%
protein-bound. The oral bioavailability of posacona-
zole is affected by food, with the greatest absorption
occurring with high-fat meals or acidic beverages.
Posaconazole is metabolized and eliminated primarily
by UDP glucoronidation, a phase II mechanism that
results in 70% of the drug undergoing biliary/fecal
excretion. The drug is minimally metabolized by the
CYP3A4 enzyme system [113].
Of the antifungals, posaconazole and fluconazole
produce milder drug–drug interactions. One of the
few interactions is with phenytoin, which acts as
a CYP3A4 inducer. Case reports have suggested that
coadministration of phenytoin and posaconazole leads
to decreased posaconazole levels; thus, a 20% decrease
in the phenytoin dosage is advised [114,115]. Of note,
concurrent use of agents that alter gastric pH, such as
H2 blockers and PPIs, may decrease the systemic
exposure to posaconazole [116]. Other interactions
with posaconazole are listed in Table 6 [114,115].
Echinocandins (Caspofungin and Micafungin)
Caspofungin and micafungin are antifungals that
inhibit b(1,3)-D-glucan synthesis of the fungal cell
wall. Caspofungin is slowly metabolized by hepatic hy-
drolysis and N-acetylation. These metabolites are fur-
ther degraded before40% is eliminated renally [117].
Micafungin is metabolized by multiple enzymes; most
of its active metabolites are formed by arylsulfatase,
catechol-O-methyltransferase, and hydroxylation. It
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zyme, and thus theoretically can interfere with the
other drugs oxidized by this enzyme [118].
Caspofungin has not been shown to inhibit any of
the CYP450 isoenzymes in vitro and has limited inter-
action on its substrates in vivo; thus, it has minimal sig-
nificant drug interactions [117]. In two clinical studies,
cyclosporine increased the AUC of caspofungin by
35%, but serum concentrations were normal [64,
119]. In a healthy volunteer study, subjects were
found to have elevated transaminase concentrations
when exposed to the drug combination [64]. A
follow-up study with lower doses of caspofungin did
not suggest that the combination led to transaminitis
[119]. In contrast to its interaction with cyclosporine,
caspofungin has been shown to decrease tacrolimus se-
rum levels to a greater degree, but no adverse clinical
effects of this interaction have been reported. Merck
currently recommends tacrolimus over cyclosporine
for use in combination with caspofungin, with routine
monitoring of tacrolimus levels [52]. According to
Merck’s analysis, even though caspofungin is not me-
tabolized by the CYP450 system, when given concur-
rently with drugs that induce the enzyme system, such
as dexamethasone or phenytoin, the 70-mg/day dosage
should be used [52].
Although micafungin is a mild CYP450 inhibitor,
very few interactions have been reported in the liter-
ature. Formal pharmacokinetic studies with healthy
volunteers have indicated that micafungin is a very
mild inhibitor of cyclosporine metabolism [120]. A
study of micafungin as fungal prophylaxis of HSCT
recipients found no increase in liver function test
values or clinical effects from this inhibition [121].
An important interaction for HSCT physicians is
that with sirolimus. Based on the manufacturer’s in-
formation, the AUC of sirolimus is increased by
20% with the concurrent use of micafungin and si-
rolimus [122], calling for close monitoring of siroli-
mus levels and toxicity and appropriate dosage
adjustments [122].Antibiotics
Although there are very few known pharmacoki-
netic drug interactions related to the common antibi-
otics used by HSCT physicians, some of the known
interactions can have serious consequences and merit
discussion.
Fluoroquinolones
Many reported interactions have been associated
with the use of fluoroquinolones [88,96,123]. One
concern is that fluoroquinolones increase the QTc
interval in some patients [96]. Concomitant use of flu-
oroquinolones and another agent known to prolong
the QTc interval call for close electrocardiographymonitoring for increased QTc interval. Drugs associ-
ated with prolonged QTc interval include the azoles,
antiemetics (eg, prochlorperazine), methadone, fo-
scarnet, pentamidine, and tyrosine kinase inhibitors,
including dasatinib and nilotinib [43,96].
Fluoroquinolone absorption is reduced by the co-
administration of products containing divalent cations,
including aluminum, calcium, magnesium, and iron.
Thus, fluoroquinolones should be given at least 2
hours before or 2 hours after ingestion of antacids,
supplements, or dairy products [123].
Caution has historically been advised with coad-
ministration of older fluoroquinolones, such as gati-
floxacin, and oral nonsulfonylureas and sulfonylureas.
Episodes of clinically significant hypoglycemia with
serious consequences, including death, were reported
in the postmarketing period in patients treated con-
comitantly with gatifloxacin and these antidiabetic
agents [124]. Similar outcomes have not been reported
with the newer fluoroquinolones, and so these strin-
gent precautions are no longer enforced.
Fluoroquinolones have also been reported to cause
tendinosis/tendinitis [88]. Reports have suggested that
this effect is increased in elderly individuals who are
taking corticosteroids, in whom this combination
should be monitored closely. As discussed previously,
an interaction between ciprofloxacin and cyclosporine
has been reported in the literature. This probably is
not a pharmacokinetic interaction, because the 2 drugs
are metabolized by different hepatic enzymes [69]. Al-
though a pharmacodynamic interaction is possible, it
has not been clearly described, and the renal insuffi-
ciency reported in some studies most likely resulted
from inappropriate medication dosing [69]. At this
time, we believe that concomitant use of these agents
is safe.Metronidazole
Metronidazole is a nitroimidazole antibiotic selec-
tively taken up by anaerobic bacteria and protozoa. It
undergoes an intracellular reduction reaction that
deprives the organism of required reduction products,
leading to death. Metronidazole undergoes significant
metabolism in the liver by hydroxylation, oxidation,
and glucuronide conjugation. Its major metabolite,
2-hydroxymethyl metronidazole, has both anti-
bacterial and antiprotozoal activity. Approximately
80% of metronidazole is excreted in the urine
(20% unchanged), and 5% to 15% is eliminated in fe-
ces [125].
Although metronidazole is not clearly metabolized
by the CYP450 isoenzyme system, its drug interactions
are a result of interactions at this site. Interactions with
drugs metabolized by the CYP3A4 and CYP2C9 sub-
families have been reported [36,95]. One important
pharmacokinetic interaction is with busulfan,
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glucuronide conjugation and leading to elevated
busulfan levels [12,16]. Other interactions of concern
are with the calcineurin inhibitors cyclosporine and
tacrolimus, with reports of increased cyclosporine,
sirolimus, and tacrolimus levels when used
concomitantly with metronidazole [36]. Close moni-
toring of serum levels is a prudent policy when these
drugs are administered concurrently.
Antivirals
Acyclovir and Valacyclovir
Acyclovir is a synthetic purine nucleoside used to
halt the replication of herpes viral DNA. Acyclovir is
minimally metabolized in the kidney by alcohol dehy-
drogenase and aldehyde dehydrogenase. Approxi-
mately 85% is excreted unchanged in the urine via
renal tubular secretion and glomerular filtration
[126]. Valacyclovir, an L-valyl ester prodrug of acyclo-
vir, undergoes rapid first-pass intestinal and/or hepatic
hydrolysis to its metabolites acyclovir and L-valine. It
is metabolized to a much lesser extent by aldehyde ox-
idase and by alcohol and aldehyde dehydrogenase. It is
three to five timesmore potent than acyclovir and is ex-
creted primarily by the kidney in the form of acyclovir
[126]. Acyclovir has very few clinically important drug
interactions, and no specific clinically significant phar-
macokinetic drug reactions have been reported for va-
lacyclovir [127].
Ganciclovir and Valganciclovir
Ganciclovir is an acyclic nucleoside analogue of 2’-
deoxyguanosine that inhibits replication of cytomega-
lovirus (CMV) and herpes simplex virus. Ganciclovir is
metabolized mainly by three cellular enzymes: a deox-
yguanosine kinase induced by CMV-infected cells,
guanylate kinase, and phosphoglycerate kinase. Ganci-
clovir is poorly absorbed, with an oral bioavailability of
only 5% to 9%. Valganciclovir, the oral prodrug of
ganciclovir, is hydrolyzed to ganciclovir in the plasma
after administration. Pharmacokinetic studies have
shown that valganciclovir has similar systemic expo-
sure to i.v. ganciclovir [128].
Few drug interactions for ganciclovir and valganci-
clovir have been reported in the literature [127]. A the-
oretical risk of an interaction between ganciclovir and
mycophenolate mofetil as a result of competition for
renal tubular secretion was examined but deemed not
clinically relevant in a small study of kidney transplan-
tation recipients [129]. A nonpharmacokinetic interac-
tion of clinical significance worth noting is that
between ganciclovir and imipenem. Generalized sei-
zures were reported in six patients given imipenem-
cilastatin concurrently with ganciclovir [130]; thus,
these two drugs should be not be used concurrently
if other treatment options are available.Famciclovir
Famciclovir, a guanosine nucleoside analogue, is
the prodrug of penciclovir, which has antiviral activity
against herpes simplex virus 1, herpes simplex virus 2,
varicella-zoster virus, and Epstein-Barr virus. Famci-
clovir is rapidly phosphorylated in virus-infected cells
to the active form, penciclovir triphosphate, and un-
dergoes extensive catalysis in the liver by aldehyde ox-
idase, thereby avoiding competition with other agents
for the CYP450 enzyme system. Approximately 73%
of famciclovir is excreted renally, with the remaining
27% excreted in feces. No clinically significant drug
interactions have been associated with famciclovir
[131].
Foscarnet
Foscarnet sodium is an inorganic pyrophosphate
analogue that inhibits herpes viruses andHIV. It inter-
acts directly with herpes virus DNA polymerase or
HIV reverse transcriptase to inhibit viral nucleic acid
synthesis. Between 3% and 28% of foscarnet is seques-
tered in bone, and 80% is eliminated unchanged in
the urine [132]. Most drug interactions described are
pharmacodynamic in nature. Similar to the azoles
and fluoroquinolones, foscarnet has been associated
with prolonged QTc interval; thus, caution is advised
when it is used with another agent that also prolongs
the QTc interval.Total Body Irradiation
Total body irradiation (TBI) is an important com-
ponent of many myeloablative conditioning regimens.
Several rat studies have suggested that TBI may alter
the enzymatic metabolism of drugs, with reduced rates
of oxidative demethylation and hydroxylation, but
with no effect on the hepatic CYP450 enzyme system
[133,134]. High-dose cyclophosphamide, often given
immediately after TBI, is dependent on the CYP450
isoenzyme system for degradation to its active meta-
bolite. A small study of 10 bone marrow transplanta-
tion recipients given high-dose cyclophosphamide
the day after the last fraction of TBI reported no
change in levels of the cyclophosphamide metabolite
4-hydroxycyclophosphamide [135].
Although TBI might not affect the metabolism of
cyclophosphamide itself, the effects of hepatic sinusoi-
dal damage might be potentiated by the interaction be-
tween these two modalities. When used alone, neither
high-dose cyclophosphamide nor TBI at 12-15 Gy
causes significant liver injury; however, when used
together, the glutathione reduction caused by cyclo-
phosphamide renders the hepatocytes vulnerable to
radiation damage [136,137]. We recommend routine
monitoring for signs and symptoms of hepatic
veno-occlusive disease when using this conditioning
regimen.
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Drug Metabolism in the Elderly
HSCT has become increasingly safe and is now of-
fered to older patients, including those in the seventh
and eighth decades of life. Drug interactions are espe-
cially important in this population, given the age-
related changes in the physiology of drug metabolism
related to the progressive decline in the efficiency of
multiple organ systems. Age-related pharmacokinetic
and pharmacodynamic changes further complicate
drug therapy in this population.
Liver metabolism declines due to decreased liver
mass and blood flow. A decrease inmass leads to less ef-
fective phase I metabolism of drugs, and reduced blood
flow results in a reduction in first-pass metabolism. Ge-
netic enzyme-related metabolism through the CYP450
isoenzyme system seems to be relatively well preserved
throughout the life span, as do phase II pathways, such
as glucuronidation and acetylation [138,139]. Kidney
mass and the number of glomeruli decrease by 30%
by age 80 years. This is associated with reductions in
glomerular filtration rate and blood flow, resulting in
decreased renal elimination of drugs [140]. Age-related
increases in body fat and decreases in lean body mass
and total body water lead to an increased volume of dis-
tribution andhalf-life of lipophilic drugs andadecreased
volume of distribution of hydrophilic drugs [141].
In terms of the pharmacokinetics of immunosup-
pressant agents in the elderly population, one study
of cyclosporine in solid organ transplantation recipi-
ents found a clinically relevant effect of age on drug ex-
posure or changes in pharmacokinetics. In a study of
25 renal transplantation recipients, the target cyclo-
sporine level was reached with lower doses in the recip-
ients aged .65 years compared with those aged\65,
presumably related to the 34% lower clearance of cy-
closporine in the older recipients [142]. Although
this finding suggests that lower doses may be appropri-
ate in older patients, our current recommendation is to
initiate treatment at the standard dosage until further
evidence is elucidated.
To date, no study with tacrolimus has shown an
impact of age on pharmacokinetic outcomes. A popu-
lation pharmacokinetic study of 22 renal transplanta-
tion recipients using a Bayesian approach found an
inverse relationship between sirolimus clearance and
age [142]. This result differed from that of another
study showing no age-related difference in sirolimus
metabolism [143]; thus, until further evidence is gath-
ered, we do not recommend changing the sirolimus
dosage in elderly patients. Although elderly individuals
exhibit no definite pharmacokinetic differences in the
metabolism of calcineurin inhibitors, they do show
some pharmacodynamic differences in drug responses,
which contribute to the various unique toxicities seenin by this population. An example of this is the in-
creased susceptibility of elderly patients to
tacrolimus-induced neurotoxicity [144].
Drug Metabolism in Children
Children metabolize drugs differently than adults,
and a fundamental understanding of developmental
pharmacology is needed to safely treat pediatric
HSCT recipients. Changes in drug absorption, dis-
tribution, metabolism, and elimination during chi-
ldhood further complicate the situation [145-147].
Chemotherapy and many medications provided
during hospitalization for HSCT are delivered i.v.;
however, most drugs administered after discharge are
given enterally. The slower gastric emptying time in
children may result in slower absorption and delayed
onset of medication action [145-147]. This is
especially true in young infants. In addition, infants
have a higher gastric pH than older children and
adults and immature biliary function, both of which
can affect drug absorption.
A medication’s volume of distribution is affected
by the patient’s body composition. Compared with
older children and adults, younger children have less
fat, more total body water, and larger extracellular
compartments, resulting in an increased volume of dis-
tribution for nonlipophilic drugs and the need for
higher weight-based dosing to achieve therapeutic
levels [145]. The difference in the volume of distribu-
tion for lipophilic drugs is less pronounced. Other fac-
tors affecting the distribution of medications in
younger children include age-specific differences in
levels of drug transporters and circulating plasma
proteins involved in drug binding [146,147].
CYP450 expression changes during childhood
[148]. Infants commonly have immature metabolic en-
zymes, resulting in decreased drug clearance and the
need for regular readjustment of dosing intervals or
doses. SomeCYP450 enzymes are expressed during fe-
tal development and diminish during infancy [149];
others, such as CYP3A5 and CYP2A6, are present
throughout the fetal period and increase shortly after
birth [149]. CYP3A4 is one of a group of enzymes
that are expressed shortly before birth and increase
rapidly after delivery [149]. Toddlers and young
school-aged children frequently have increased enzy-
matic activity and higher medication doses and shorter
dosing intervals. Closemonitoring of serumdrug levels
in children is essential given the age-based differences
and individual variations in enzymatic activity.
Differences in renal drug elimination are limited
primarily to infants, who have an immature glomerular
filtration rate, which may result in decreased clearance
and increased levels of renally cleared medications.
Adult glomerular filtration rate levels are typically
achieved by age 12 months [145].
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and adults may be illustrated most clearly by the clear-
ance of busulfan [150,151]. The plasma clearance rate
of oral busulfan may be up to five times faster in
children than in adults, with lower AUC values in
children. Young children may metabolize busulfan
up to four times faster than adults [152]. Due in part
to the inconsistency of busulfan clearance and metab-
olism, most pediatric centers administer i.v. busulfan
and closely monitor serum drug levels [153].
Studies have found faster clearance of sirolimus
in children and have shown that the addition of
sirolimus to a tacrolimus-containing regimen
lowers tacrolimus levels, especially in young children
[154-156]. Other studies have shown that higher
doses of tacrolimus and MMF are often needed to
achieve therapeutic levels in children compared
with adolescents and adults [157,158]. These findings
underscore the need for frequent drug level
monitoring in children who have undergone HSCT.CONCLUSION
Patients undergoing HSCT are at risk for adverse
effects due to drug–drug interactions because their
treatment typically involves complexmedical regimens
that include drugs with a narrow therapeutic index.
Increased understanding of the enzymatic pathways re-
sponsible for drug metabolism may help transplanta-
tion physicians reduce preventable adverse outcomes
related to harmful interactions. Unfortunately, choos-
ing an alternative option often is not possible, and thus
treatment may need to be adjusted to minimize poten-
tial interactions. Transplantation centers should con-
sider implementing a comprehensive team approach
for developing and updating treatment regimens.
This team should constantly evaluate its protocols,
monitor drug levels, develop a reporting system for
abnormal laboratory values, compare current ap-
proaches to evidence available in the literature, and in-
vestigate deviations from established standards of care.
Such an approach will promote patient safety, mini-
mize complications, and optimize treatment outcomes.ACKNOWLEDGMENTS
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